瑞康医药董事、副总裁韩春林辞职；百利天恒定向增发获上交所审核通过｜医药早参

Group 1 - ZEGFROVY® (suwotini) by Dige Pharmaceutical has been included in the latest NCCN guidelines for the treatment of NSCLC with EGFR exon 20 insertion mutations, marking it as the only small molecule targeted therapy for this indication in global authoritative lung cancer guidelines [1] - The approval signifies the feasibility of "China R&D, global standards," suggesting that new drug companies should plan international clinical and registration strategies early [1] - There is a call for the establishment of a tiered evaluation system for innovative drugs at the policy level, providing institutional incentives for source innovation [1] Group 2 - Hanchun Lin, Vice President and Director of Ruikang Pharmaceutical, has resigned due to personal reasons, and will no longer hold any positions within the company or its subsidiaries [2] - The resignation follows recent announcements regarding "executive detention notices" and "share repurchase announcements," raising questions about potential connections to these events [2] Group 3 - Baili Tianheng has received approval from the Shanghai Stock Exchange for its targeted stock issuance, indicating that its financing plan has taken a significant step forward [3] - The approval aligns with regulatory requirements, and if the subsequent registration by the CSRC is successful, it will enhance the company's capital strength to support R&D investments or business expansion [3] - As an innovative pharmaceutical company, Baili Tianheng has been intensifying its new drug development efforts, and this financing may further support its innovation pipeline [3] Group 4 - *ST Suwu has received an administrative penalty notice from the CSRC for failing to disclose the actual controller, inflating revenue, costs, and profits, and not disclosing non-operating fund occupation by related parties as required [4] - The company may face mandatory delisting due to significant violations of the Shanghai Stock Exchange listing rules, along with potential investor compensation risks [4]